StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
NAGENiagen Bioscience, Inc.
stockpulse.co.kr
Nasdaq
$2.45▲ 1.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $195.1MShares out 79.6M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

2
  • 8.4After-hours26.08.05 05:04
    10-QEarnings#●●●#●●●

    Niagen Bioscience, Inc.

    Niagen Bioscience는 2026년 6월 12일, 로스앤젤레스 소재 사무실에 대해 2027년 4월 1일부터 2035년 1월 31일까지의 7년 10개월 임대차 계약을 체결했습니다. 해당 계약에 따라 회사는 2027년 4월부터 월 44,897달러의 임대료를 지급하며, 65,419달러의 보증금을 예치합니다.…more

    $2.45+1.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.4After-hours26.08.05 05:03
    8-KKey event

    Niagen Bioscience, Inc.

    Niagen Bioscience는 2026년 2분기 매출 2,980만 달러, 순이익 100만 달러(주당순이익 0.01달러)를 기록했습니다. 희귀 유전질환 치료제 후보물질 NB4168을 도입하고 원격 의료 플랫폼 'Niagen Plus'를 출시하는 등 사업 구조를 건강기능식품에서 항노화 제약 기업으로 전환하고 있습니다.…more

    $2.45+1.24%vs prev close
    View filingShare

1 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.30Pre-market26.09.30 21:39
    #●●●#●●●

    Niagen Bioscience Partners with Mass General Brigham for Large-Scale Clinical Trial…more

    Niagen Bioscience is collaborating with Mass General Brigham to plan a comprehensive clinical trial evaluating the effects of Niagen on healthy aging in adults aged 50 and older. The project is currently in the planning phase, with final logistics and trial design details still to be determined.…more

    $2.45+1.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.21Pre-market26.09.21 21:35

    ●●●●●●●● ●●●●● ●●●●●●

    Niagen Bioscience highlighted independent research identifying CD38 as a primary driver of NAD+ decline in aging placental tissue. The study suggests that NR supplementation can restore NAD+ levels and improve reproductive outcomes in preclinical models.…more

    $2.45+1.24%vs prev close
    ShareBenzinga
  • 8.20Pre-market26.08.20 21:36

    ●●●●●●●● ●●●●● ●●●●●●

    Niagen Bioscience announced that its Tru Niagen product is now available at GNC and Sam's Club locations across 44 states. This expansion increases consumer accessibility through both online and retail channels.…more

    $2.45+1.24%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →